Golimumab Antibody | AbD20893_hIgG1

//www.bio-rad-antibodies.com/golimumab-antibody-abd20893-higg1-hca245.html
Golimumab Antibody | AbD20893_hIgG1 gallery image 1

Human anti golimumab (drug/target complex) specificity ELISA

A microtiter plate was coated over night with various antigens at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP-conjugated Human anti golimumab (clone AbD20893_hIgG1) at a concentration of 2 µg/ml and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®

Enlarge
Golimumab Antibody | AbD20893_hIgG1 gallery image 2

Human anti golimumab (drug/target complex) specificity titration ELISA

A microtiter plate was coated over night with human TNFα, golimumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, the TNFα/golimumab complex was formed by adding 2 µg/ml golimumab to TNFα-coated wells. Detection was performed using HRP-conjugated Human anti golimumab (clone AbD20893_hIgG1) titrated to the given concentrations in PBST followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data for the binding of antibody to TNFα/golimumab is presented as the mean of three measurements

Enlarge
Golimumab Antibody | AbD20893_hIgG1 gallery image 3

Golimumab capture ELISA for Pharmacokinetic (PK) assay development

A microtiter plate was coated over night with human TNFα at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of golimumab. Detection was performed using HRP-conjugated Human anti golimumab (clone AbD20893_hIgG1) at a concentration of 2 µg/ml in HISPEC assay diluent (BUF049A) followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit®. Data for the binding of antibody to TNFα/golimumab is presented as the mean of three measurements

Enlarge
  • Golimumab Antibody | AbD20893_hIgG1 thumbnail image 1
  • Golimumab Antibody | AbD20893_hIgG1 thumbnail image 2
  • Golimumab Antibody | AbD20893_hIgG1 thumbnail image 3
  • Human anti Golimumab (Drug/Target Complex)
(Rated 0.0 out of 5 based on 0 customer reviews)
    Anti-golimumab drug-target complex antibody specifically recognizes the golimumab-TNF alpha complex and detects golimumab or biosimilars only when bound to TNF alpha. This antibody is in full immunoglobulin format and is suitable for a PK antigen capture format assay to detect bound drug.
    • Product Type
      Monoclonal Antibody
    • Clone
      AbD20893_hIgG1
    • Isotype
      IgG1
    1 Formats Available
      Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
      HCA245Edatasheet pdfdatasheet pdf0.1 mg
      HCA245
      Summary
      Secondary Antibodies
      Negative Isotype Controls
      Useful Reagents
      Positive Controls
      Histology Controls
      More Images
      References
      Reviews
      -
      • Human anti golimumab (drug/target complex), clone AbD20893_hIgG1 is a Type 3 anti-idiotypic antibody that specifically recognizes golimumab when bound to tumor necrosis factor alpha (TNFα) i.e. the drug/target complex. Clone AbD20893_hIgG1 does not recognize unbound golimumab nor free TNFα. Clone AbD20893_hIgG1 may be used to measure golimumab when captured by immobilized human TNFα or golimumab/TNFα levels in serum from patients.

        Golimumab, marketed under the brand name Simponi®, is a recombinant human IgG1/kappa monoclonal antibody approved for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. This therapeutic antibody, directed against TNFα, acts by blocking the binding of TNFα to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

        Clone AbD20893_hIgG1 is one of a range of Type 1 (HCA240, HCA241), Type 2 (HCA242, HCA243) and Type 3 (HCA244) anti-idiotypic antibodies to golimumab available from Bio-Rad and forms part of a wider and expanding portfolio of anti-idiotypic antibodies that have been developed for the detection of biotherapeutics.
      • Intended Use
      • Product Form
        Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
      • Reconstitution
      • Preparation
        Purified IgG prepared by affinity chromatography on Protein A
      • Preservative Stabilisers
        0.01% Thiomersal
      • Immunogen
        Golimumab.
      • Purity
      • Affinity
        The monovalent intrinsic affinity of AbD20893_hIgG1 was measured as KD = 53 nM by real time, label free molecular interaction analysis on immobilized golimumab in complex with human TNFα.
      • Approx. Protein Concentrations
        Antibody concentration 0.5 mg/ml
      • Reagents In The Kit
      • Preparing The Antibody
      • Test Principle
      • Buffer Solution
        Phosphate buffered saline
      • Storage
        Store at +4oC or at -20oC if preferred.
        Storage in frost-free freezers is not recommended.
        This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
      • Shelf Life
        12 months from date of despatch
      • Acknowledgements
        Sold under license of U.S. Patents 6,300,064, 6,696,248, 6,708,484, 6,753,136, European Patent 0,859,841 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany, a wholly owned subsidiary of Bio-Rad Laboratories Inc.

        Simponi® is a registered trademark of Janssen Biotech, Inc. in the USA and Merck & Co, Inc. in Europe.
      • Licensed Use
        For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
      • Regulatory
        For research purposes only
      • This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.

      • Application NameYesNoMin DilutionMax Dilution
        ELISA

      • Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
      • Technical Advice
        Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
      • Recommended Protocol
      • ELISA
        When conjugated to HRP, this product may be used in a direct ELISA to detect the golimumab/TNFα complex or to detect golimumab bound to immobilized TNFα.
        Protocol: PK antigen capture ELISA to measure bound drug exclusively
      • Immunohistology
      • Histology Positive Control Tissue
      • Immunofluorescence
      • Western Blotting
      • Instructions For Use

      Additional Golimumab Antibody Formats

      Formats Clone Applications Sizes available
      Golimumab Antibody : Purified AbD20893_hIgG1 E 0.1 mg
      • Copyright © 2016 Bio-Rad

      Recommended Secondary Antibody

        Recommended Negative Isotype Control

          Useful Reagents

            DescriptionProduct CodePack SizeApplicationsList PriceQuantity
            LYNX Rapid HRP Antibody Conjugation KitLNK005P1 Conjugation For 20mg AntibodyCJ
            LNK005P
            LYNX Rapid HRP Antibody Conjugation KitLNK001P1 Conjugation For 400µg AntibodyCJ
            LNK001P
            LYNX Rapid HRP Antibody Conjugation KitLNK003P1 Conjugation For 4mg AntibodyCJ
            LNK003P
            LYNX Rapid HRP Antibody Conjugation KitLNK006P3 Conjugations For 40µg AntibodyCJ
            LNK006P
            LYNX Rapid HRP Antibody Conjugation KitLNK002P3 Conjugations For 400µg AntibodyCJ
            LNK002P
            LYNX Rapid HRP Antibody Conjugation KitLNK004P5 Conjugations For 4mg AntibodyCJ
            LNK004P
            Human anti Golimumab (Drug/Target Complex)HCA2440.1 mgE
            HCA244
            Hispec Assay DiluentBUF049A50 mlIY
            BUF049A

            Recommended Positive Controls

              Histology Controls

                Write your review

                You may also be interested in...

                You May Also Be Interested In...